SDHD rs11214077: Understanding This Genetic Variant
The rs11214077 variant is a specific change in the DNA sequence located within the SDHD gene. Current scientific evidence classifies this variant as a benign polymorphism, meaning it is not considered a cause of hereditary cancer-predisposing syndromes.
What each genotype means
Common genetic profile
This is the most frequently observed genotype for this variant in the general population. It is classified as a benign polymorphism and is not associated with hereditary cancer-predisposing syndromes.
This is the most common genotype found across all major ancestral populations.
Benign variant carrier
This genotype is classified as a benign variant in clinical databases. It does not indicate an increased risk for hereditary cancer-predisposing syndromes related to the SDHD gene.
This genotype is observed at a low frequency in the general population.
Rare benign profile
While this genotype is rare, it is considered a benign polymorphism according to clinical evidence. It is not linked to the development of hereditary cancer-predisposing syndromes.
This is a rare genotype, occurring at a very low frequency across global populations.
What is rs11214077 and Where is it Located?
The variant rs11214077 is a single nucleotide polymorphism (SNP) found within the SDHD gene. In genetics, a SNP represents a variation at a single position in a DNA sequence among individuals. The SDHD gene is located on the long arm of chromosome 11 at position 11q23.1. This region is significant because it contains the instructions for building the SDHD protein, which is a critical component of the mitochondrial succinate dehydrogenase enzyme complex. While many variants in the SDHD gene are studied for their potential links to hereditary conditions, rs11214077 is widely documented in genomic databases as a benign polymorphism. This classification indicates that the change in the DNA sequence at this specific location does not typically disrupt the function of the SDHD protein or contribute to the development of disease in the way that pathogenic mutations do.
The Role of the SDHD Gene
The SDHD gene provides the genetic blueprint for the D subunit of the succinate dehydrogenase (SDH) enzyme. This enzyme is essential for the proper functioning of mitochondria, the powerhouses of our cells. Specifically, the SDH enzyme acts as a bridge between the citric acid cycle and the electron transport chain, two fundamental processes that convert nutrients from food into adenosine triphosphate (ATP), the primary energy currency of the cell. By anchoring the SDH complex to the mitochondrial membrane, the SDHD protein ensures that electrons are transferred efficiently to support energy production. Beyond energy metabolism, the SDH complex is involved in sensing oxygen levels within the cell. When the SDH complex is functioning correctly, it helps regulate cellular responses to low-oxygen environments. Disruptions in this gene can sometimes lead to the stabilization of hypoxia-inducible factors, which may influence cell growth and tumor development.
Research Associations and Evidence Strength
Scientific research into the SDHD gene has primarily focused on its role in hereditary paraganglioma-pheochromocytoma (PGL/PCC) syndromes. Pathogenic mutations in SDHD are well-established as causes of these conditions, which involve the growth of tumors in the neuroendocrine system. However, the evidence regarding rs11214077 is distinct from these pathogenic findings. Genomic databases and clinical research repositories classify rs11214077 as a benign variant. This means that, unlike the mutations that cause PGL/PCC, this specific SNP does not have a strong statistical association with increased cancer risk. While researchers continue to monitor variants across the genome to understand their potential impacts, current data suggests that rs11214077 is a common, non-harmful variation. It is important to distinguish between benign polymorphisms like this one and the rare, pathogenic mutations that are clinically significant for hereditary cancer syndromes.
Population Frequency
The rs11214077 variant is observed across various human populations, with a reported frequency of approximately 0.009. This frequency indicates that the variant is relatively uncommon but present in the general population. Because it is classified as a benign polymorphism, its presence is considered a normal part of human genetic diversity rather than a marker for a specific health condition. Genetic frequency can vary based on ancestral background, and large-scale genomic projects like gnomAD continue to refine these estimates as more individuals are sequenced. Understanding the frequency of such variants helps scientists establish a baseline for what is considered 'normal' variation versus what might be a rare, disease-causing mutation. For the average person, finding this variant in a genetic report is generally expected and does not typically require clinical follow-up or specialized medical intervention.
What You Can Do With This Information
Information about benign variants like rs11214077 is primarily educational. Because this variant is not associated with an increased risk of disease, it does not provide actionable medical information for you or your family. If you have received a genetic report that mentions this variant, it is helpful to view it as a piece of your unique genetic profile that falls within the range of normal human variation. You cannot use this information to diagnose or predict health outcomes. If you have concerns about your family history of cancer or other health conditions, the most effective step is to consult with a certified genetic counselor or a healthcare provider. They can help you interpret your overall genetic risk profile in the context of your personal and family medical history, rather than focusing on individual benign SNPs.
How common is this variant?
The rs11214077 variant has a population frequency of approximately 0.009, reflecting its status as a common, benign polymorphism.
Frequently asked questions
Is rs11214077 linked to cancer?
No, rs11214077 is classified as a benign polymorphism. It is not associated with the hereditary cancer-predisposing syndromes linked to pathogenic mutations in the SDHD gene.
Should I be worried if I have this variant?
There is no reason for concern. This variant is considered a normal part of human genetic diversity and does not indicate an increased risk for health problems.
Does this variant affect my mitochondria?
While the SDHD gene is involved in mitochondrial function, rs11214077 is a benign change that does not typically disrupt the function of the SDH enzyme or mitochondrial energy production.
Do I need to see a doctor about this result?
Generally, no. Because this is a benign variant, it does not require medical follow-up. However, if you have concerns about your health or family history, you should always discuss them with your primary care physician.
Sources & further reading
Educational information only, last refreshed 9/20/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs11214077?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29